Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
AuthorsBrennan, Donal J
Gallagher, William M
O'Connor, Darran P
AffiliationDept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland. firstname.lastname@example.org
Hydroxymethylglutaryl CoA Reductases
Neoplasm Recurrence, Local
Tumor Markers, Biological
MetadataShow full item record
CitationTumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. 2010, 10:125 BMC Cancer
AbstractBACKGROUND: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. METHODS: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). RESULTS: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. CONCLUSION: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens.
- Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
- Authors: Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K
- Issue date: 2008
- Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
- Authors: Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Pontén F, Millikan RC, Rydén L, Jirström K
- Issue date: 2011 Jan 31
- HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
- Authors: Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K
- Issue date: 2008 Sep 1
- HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
- Authors: Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlén M, Borgquist S, Jirström K
- Issue date: 2014 Apr 7
- HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
- Authors: Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Sundara-Rajan S, Humphries MP, Barba M, Speirs V, De Maria R, Maugeri-Saccà M
- Issue date: 2016 Oct 7